Filing Summary
Issuer mismatch: The request identifies CalciMedica, Inc., but the supplied Form 10-Q is for Graybug Vision, Inc. This summary reflects the filing provided, not a CalciMedica filing.
Business context and reporting period
Graybug Vision is a clinical-stage biopharmaceutical company developing sustained-release treatments for retinal and optic-nerve diseases. This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2021; it was signed November 12, 2021. The company had no product revenue and devoted substantially all resources to research and development and raising capital.
Financial results and liquidity
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | No product revenue reported | No product revenue reported | No product revenue reported | No product revenue reported |
| Research and development expense | $4.0 million | $4.8 million | $14.6 million | $15.5 million |
| General and administrative expense | $4.0 million | $2.1 million | $12.6 million | $5.2 million |
| Total operating expenses | $8.0 million | $6.8 million | $27.2 million | $20.7 million |
| Net loss | $8.0 million | $4.7 million | $27.1 million | $18.4 million |
| Net loss per common share | $0.38 | $2.52 | $1.28 | $13.74 |
At September 30, 2021, cash and cash equivalents were $11.5 million and short-term investments were $61.1 million, totaling $72.6 million in cash, cash equivalents and short-term investments. Total assets were $76.6 million; current liabilities were $4.5 million; total liabilities were $4.5 million. The filing reports no borrowings or credit facility. Accumulated deficit was $160.5 million.
For the first nine months of 2021, operating cash use was $22.5 million, investing cash use was $35,000, and financing provided $614,000, mainly from option exercises. Cash and cash equivalents decreased $22.0 million. No operating margin or other revenue-based margin is meaningful because the company reported no product revenue.
Changes versus the prior comparable period
- Q3 operating expenses increased 18% year over year and net loss increased $3.3 million. G&A rose 94%, while R&D declined 15% as the GB-102 treatment phase had been completed.
- For the nine-month period, operating expenses increased 32% and net loss increased $8.8 million. Higher G&A reflected increased stock-based compensation, public-company insurance costs, headcount and a write-off of equipment deposits and related commitments.
- The 2020 comparison included a $2.1 million Q3 gain from the change in fair value of a preferred-stock tranche obligation and $2.4 million of cumulative preferred dividends attributable to common stockholders. The tranche obligation expired in September 2020.
- Cash and cash equivalents plus short-term investments fell from $95.0 million at December 31, 2020 to $72.6 million at September 30, 2021.
Outlook, commentary and risks
- Management said existing cash, cash equivalents and short-term investments were expected to fund the current operating plan for at least 12 months from the filing’s issuance. The estimate depends on assumptions and on not proceeding with GB-102 Phase 3 trials absent partner funding. The company intends to seek additional financing and collaborations; funding may not be available on acceptable terms or at all.
- In March 2021, Graybug decided not to fund the significant investment needed to start two GB-102 Phase 3 trials in late 2021. Further clinical trials of GB-102 for wet AMD require partner funding. The company reported topline results from the Phase 2b six-month observational period in September 2021; the supplied filing text does not give a clear numerical summary of those results.
- Graybug stopped further development of GB-103, citing the 12-month-or-longer duration observed with GB-102 in its 18-month Phase 2b trial. It planned to fund GB-102 reformulation and preclinical work and expected to begin a Phase 1 trial of GB-401 for glaucoma no earlier than the second half of 2022.
- A $2.2 million expense resulted from terminating vendor and manufacturing commitments: approximately $1.3 million of equipment deposits and $0.9 million of other commitments and cancellation fees. The company reported no unpaid cancellation costs and did not anticipate any.
- Key risks include clinical and regulatory uncertainty, the need to secure a GB-102 partner and additional capital, manufacturing and supply challenges, competition, and possible COVID-19-related disruption to trials or operations. Management said it did not expect a material long-term COVID-19 impact based on its assessment at the time, while noting continued uncertainty.
- The company reported no material legal proceedings. Management concluded disclosure controls and procedures were effective and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Graybug Vision, Inc., not CalciMedica, Inc.
- Review the complete GB-102 Phase 2b results, including the September observational-period data, safety findings and implications for any partner-funded development.
- Verify the status and terms of any prospective GB-102 partnership and the timing and availability of additional financing.
- Assess whether management’s stated cash runway remains reasonable in light of actual spending, development plans and future commitments.
- Check progress and timing for GB-401 and the rationale and consequences of discontinuing GB-103.